ERBB2 and aneurysmal bone cyst: Concordantly, CDK4/6 inhibitors exhibit robust and durable clinical activity in treating HR-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced breast cancer (ABC) [5–8].